HB 2349 West Virginia House of Delegates · 2025 Regular Session

To offer long-acting reversible contraception to patients receiving methadone and suboxone at the treatment facility for the methadone and suboxone

HB 2349 requires opioid treatment programs licensed under West Virginia law to offer long-acting reversible contraception (LARC), such as IUDs or implants, to patients receiving methadone or suboxone treatment. This applies directly to patients in medication-assisted treatment programs and the facilities operating those programs. The bill amends licensing rules (§16B-13-3 and §16B-13-5) to mandate that facilities provide information about and access to LARC options as part of their standard services. It does not specify which contraception methods must be offered, only that facilities must make LARC available to eligible patients.

Issues: ✓ Healthcare

Bill status passed 3 of 5 stages cleared

Introduction

Feb 2025

Committee Review

Apr 2025

House of Delegates Passage

Mar 2025

Senate Passage

Governor

Introduced Feb 13, 2025 Last action Apr 11, 2025

Maddy AI version diff · 4 comparisons

What changed between versions

Committee Substitute for the Committee Substitute → hb2349 hfa worrell 3-20 _1 adopted.htm · 2 edits

MINOR

The document shows a legislative amendment process for HB 2349, which deals with opioid treatment programs. The changes indicate a procedural vote where Delegate Worrell moved to add a requirement for offering long-acting reversible contraception to patients recovering from addiction, but this amendment was rejected. The core bill text regarding opioid treatment program licensing remains unchanged.

REQUIREMENT

A proposed amendment requiring opioid treatment programs to offer long-acting reversible contraception to patients recovering from addiction was rejected during committee review.

TECHNICAL

The document header changed from 'Committee Substitute for the Committee Substitute' to 'HB2349 HFA Worrell 3-20 #1', indicating a procedural revision in the legislative tracking system.

Introduced Version → Engrossed Committee Substitute for the Committee Substitute · 10 edits · Mar 21, 2025

MAJOR

The bill was substantially rewritten and expanded during committee review. The original version focused narrowly on requiring MAT programs to offer long-acting reversible contraception, while the engrossed version now includes comprehensive operational requirements covering licensing, staff qualifications, patient privacy, drug testing, and detailed contraceptive counseling protocols. This represents a significant expansion of regulatory oversight for medication-assisted treatment programs in West Virginia.

Scope change

The bill's scope expanded from a narrow focus on contraceptive offerings to comprehensive operational requirements for all medication-assisted treatment programs, including new sections on licensing procedures, staff qualifications, patient records, and drug testing protocols.

REQUIREMENT

Added detailed requirements for medical director qualifications, including specific training mandates for physicians prescribing partial opioid agonists.

Added comprehensive staff qualification requirements for counseling personnel, including specific education levels and certification pathways.

Added mandatory fingerprinting and criminal background check requirements for all employees.

Added detailed patient record-keeping requirements including coordination of care agreements that must be reviewed annually.

Added specific protocols for long-acting reversible contraception including shared decision-making counseling and referral systems for programs without qualified providers.

Added requirements for quarterly review of controlled substance monitoring databases to prevent patients from obtaining medications from multiple sources.

Added prohibition on employing physicians with inactive DEA numbers or probationary restrictions.

Modified insurance billing requirements to include documentation of uninsured patients and option to begin treatment before billing.

Added requirement for physician consultation with obstetrical or gynecological providers when treating patients who are not their own OB/GYN patients.

Added requirement for documenting clinical justification when prescribing buprenorphine doses exceeding 16 milligrams per day.

Floor votes · House of Delegates Mar 21, 2025

How they voted

91–4

Passed · 5 other

Total votes 100

Mar 21, 2025

D Democratic9

9 Yea

100% Yea

R Republican91

82 Yea 4 Nay 5

90% Yea

Vote distribution

All Yea All Nay Mixed No data

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Amendments

Apr 9, 2025

Upper · Passed

Reported do pass, with title amendment

upper

Apr 7, 2025

Committee

To Finance

upper

Apr 7, 2025

Upper · Passed

Reported do pass, but first to Finance

upper

Mar 24, 2025

Committee

To Health and Human Resources

upper

Mar 24, 2025

Committee

To Health and Human Resources then Finance

upper

Mar 24, 2025

Introduced

Introduced in Senate

upper

Mar 21, 2025

Lower · Passed

Passed House (Roll No. 132)

lower

Mar 20, 2025

Lower · Passed

Amendment adopted (Voice vote)

lower

Mar 20, 2025

Introduced

Amendment reported by the Clerk

lower

Mar 19, 2025

Lower · Passed

By substitute for substitute, do pass

lower

Mar 18, 2025

Lower · Passed

By substitute, do pass

lower

Mar 13, 2025

Committee

To House Health and Human Resources

lower

Feb 14, 2025

Committee

To House Public Health

lower

Feb 13, 2025

Committee

To House Health and Human Resources

lower

Feb 13, 2025

Introduced

Introduced in House

lower

Feb 13, 2025

Committee

To Health and Human Resources

lower

1 primary · 10 co-sponsors